drugset / Trial / NCT05758428

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects

NCT05758428

Phase 1 Completed 28 enrolled Nuance Pharma (shanghai) Co., Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 1, open-label, parallel cohort study to evaluate the PK, safety and tolerability of nebulized ensifentrine following administration of single and multiple doses in healthy Chinese male subjects.

Timeline

Start
2023-03-06
Primary completion
2023-04-18
Completion
2023-04-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Ensifentrine Unknown 1.5 mg Other
Subject Ensifentrine Unknown 3 mg Other
Subject Ensifentrine Unknown 6 mg Other